Amneal Revenue Jumps 11.7% in Q3, Refinancing Costs Hit Profit

TL;DR

**AMRX's Q3 revenue surge is overshadowed by refinancing costs, making it a mixed bag for investors eyeing growth but wary of debt.**

AI Summary

Amneal Pharmaceuticals, Inc. (AMRX) reported a significant increase in net revenue for the three months ended September 30, 2025, reaching $784.5 million, up from $702.5 million in the prior year, a 11.7% increase. For the nine months, net revenue grew to $2.20 billion from $2.06 billion, a 6.8% increase. Despite this revenue growth, the company experienced a net loss before income taxes of $5.2 million for the quarter, a sharp decline from a $15.4 million income in the same period last year, primarily due to a $31.4 million loss on refinancing. However, net income attributable to Amneal Pharmaceuticals, Inc. for the quarter was $2.4 million, a turnaround from a net loss of $0.2 million in Q3 2024. Year-to-date, net income attributable to AMRX was $37.0 million, a substantial improvement from a $85.8 million loss in the prior year. Operating income for the quarter decreased to $70.3 million from $88.8 million, while for the nine months, it significantly increased to $282.1 million from $173.5 million. The company's cash and cash equivalents increased to $201.2 million as of September 30, 2025, from $110.6 million at December 31, 2024, driven by $209.7 million in net cash provided by operating activities over nine months. Long-term debt, net, increased to $2.57 billion from $2.16 billion, reflecting recent financing activities.

Why It Matters

Amneal's robust revenue growth of 11.7% quarter-over-quarter signals strong product demand and market penetration, which is crucial for investors looking for top-line expansion in the competitive pharmaceutical sector. However, the $31.4 million loss on refinancing and increased long-term debt to $2.57 billion could raise concerns about financial leverage and future interest expenses, potentially impacting profitability and cash flow available for other investments or shareholder returns. For employees, continued revenue growth could indicate job stability and potential for expansion, while customers benefit from the availability of Amneal's generic and specialty pharmaceutical products. In the broader market, Amneal's performance reflects the ongoing dynamics of the generics industry, where pricing pressures are constant, and strategic financial management is key to maintaining competitiveness against rivals like Teva and Sandoz.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant increase in long-term debt to $2.57 billion from $2.16 billion at year-end 2024, coupled with a $31.4 million loss on refinancing in Q3 2025. While net income improved, the substantial debt load and associated interest expense of $184.9 million for the nine months ended September 30, 2025, pose a material financial risk, as highlighted in the 'Summary of Material Risks' section regarding 'our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future'.

Analyst Insight

Investors should closely monitor Amneal's debt management strategies and future interest rate exposures, given the increased long-term debt and refinancing loss. While revenue growth is positive, assess if the operational improvements can consistently outpace the financial costs associated with their leverage. Consider if the current valuation adequately discounts these financial risks.

Financial Highlights

revenue

$784.5M

operating Margin

8.96%

total Debt

$2.57B

net Income

$2.4M

eps

$0.01

gross Margin

34.9%

cash Position

$201.2M

revenue Growth

+11.7%

Revenue Breakdown

Key Numbers

• $784.5M — Net revenue for Q3 2025 (Increased by 11.7% from $702.5M in Q3 2024)
• $2.20B — Net revenue for nine months ended Sept 30, 2025 (Increased by 6.8% from $2.06B in the prior year period)
• $2.4M — Net income attributable to AMRX for Q3 2025 (Turnaround from a $0.2M net loss in Q3 2024)
• $37.0M — Net income attributable to AMRX for nine months ended Sept 30, 2025 (Substantial improvement from an $85.8M loss in the prior year period)
• $31.4M — Loss on refinancing for Q3 2025 (Significant factor in quarterly pre-tax loss)
• $2.57B — Long-term debt, net, as of Sept 30, 2025 (Increased from $2.16B at Dec 31, 2024)
• $201.2M — Cash and cash equivalents as of Sept 30, 2025 (Increased from $110.6M at Dec 31, 2024)
• $209.7M — Net cash provided by operating activities for nine months ended Sept 30, 2025 (Increased from $177.0M in the prior year period)
• $184.9M — Interest expense, net, for nine months ended Sept 30, 2025 (Reflects cost of debt)
• 314,362,920 — Shares of Class A common stock outstanding as of Oct 31, 2025 (Total shares outstanding)

Key Players & Entities

• Amneal Pharmaceuticals, Inc. (company) — registrant
• SEC (regulator) — filing oversight
• Nasdaq Stock Market LLC (company) — exchange where AMRX is registered
• Amneal Group (company) — controlling shareholder of AMRX
• Teva (company) — competitor in the pharmaceutical industry
• Sandoz (company) — competitor in the pharmaceutical industry

FAQ

Risk Factors

• Loss on Refinancing [medium — financial]: The company incurred a significant $31.4 million loss on refinancing during the three months ended September 30, 2025. This loss directly contributed to the reported net loss before income taxes of $5.2 million for the quarter, a reversal from a $15.4 million income in the prior year.
• Increased Long-Term Debt [medium — financial]: Long-term debt, net, increased to $2.57 billion as of September 30, 2025, up from $2.16 billion at December 31, 2024. This increase reflects recent financing activities and raises the company's leverage.
• Cost of Goods Sold Increase [medium — operational]: Cost of goods sold rose to $510.5 million for Q3 2025 from $432.9 million in Q3 2024, and to $1.39 billion year-to-date from $1.31 billion. This increase outpaced revenue growth, impacting gross profit margins.
• SG&A Expense Growth [medium — operational]: Selling, general, and administrative expenses increased to $137.8 million in Q3 2025 from $118.7 million in Q3 2024, and year-to-date to $380.4 million from $347.7 million. This growth in operating expenses also pressured profitability.
• Opioid Litigation Liability [high — regulatory]: The company has a restricted cash balance of $24.2 million associated with a settlement in principle for opioid cases. While a resolution is in progress, ongoing legal and settlement costs represent a significant financial and operational risk.
• Interest Expense [medium — financial]: Interest expense, net, was $62.8 million for Q3 2025 and $184.9 million year-to-date. Despite a slight decrease year-over-year for the quarter, the substantial interest burden reflects the company's significant debt load.

Industry Context

Amneal Pharmaceuticals operates in the highly competitive generic and specialty pharmaceutical market. The industry is characterized by intense pricing pressure, regulatory hurdles for drug approvals, and the constant need for innovation and efficient manufacturing. Companies like Amneal focus on developing and commercializing a broad portfolio of products to diversify revenue streams and mitigate risks associated with individual product lifecycles.

Regulatory Implications

Amneal faces ongoing regulatory scrutiny common in the pharmaceutical industry, including FDA compliance for manufacturing and product quality. The company's past involvement in opioid litigation also highlights potential liabilities and the need for robust compliance and risk management strategies to navigate legal and regulatory challenges.

What Investors Should Do

1. Monitor debt levels and refinancing strategies.
2. Analyze the drivers of revenue growth and gross margin.
3. Assess the impact of one-time charges and legal settlements.
4. Evaluate the improvement in operating income year-to-date.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the latest 10-Q, showing revenue growth but a quarterly pre-tax loss due to refinancing costs, alongside improved net income attributable to AMRX.
• 2025-12-31: End of Fiscal Year 2024 — Reference point for year-end cash and debt balances, showing a significant increase in cash and long-term debt by Q3 2025.

Glossary

Net revenue

The total revenue earned by the company after deducting returns, allowances, and discounts. (Key indicator of top-line performance and market demand for Amneal's products.)

Operating income

Profitability from core business operations before accounting for interest, taxes, and other non-operating expenses. (Measures the efficiency and profitability of the company's primary business activities.)

Loss on refinancing

A charge incurred when a company retires existing debt and issues new debt with different terms, often at a higher cost or with associated fees. (A significant one-time expense that impacted Amneal's quarterly pre-tax income.)

Net income (loss) attributable to Amneal Pharmaceuticals, Inc.

The portion of the company's net income or loss that belongs to its common shareholders after accounting for non-controlling interests. (The bottom-line profitability available to Amneal's shareholders.)

Cash and cash equivalents

Highly liquid investments with maturities of three months or less at the time of purchase, including cash on hand and in banks. (Indicates the company's short-term liquidity and ability to meet immediate obligations.)

Long-term debt, net

The total amount of money borrowed by the company that is due more than one year from the balance sheet date, net of any unamortized discount or premium. (Represents the company's long-term financial obligations and leverage.)

Net cash provided by operating activities

The net amount of cash generated from the normal day-to-day business operations of the company. (A crucial measure of the company's ability to generate cash internally to fund its operations and investments.)

Non-controlling interests

The portion of equity in a subsidiary that is not attributable to the parent company, often representing ownership by other shareholders. (Affects the net income attributable to the parent company's shareholders.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Amneal Pharmaceuticals has demonstrated robust top-line growth, with net revenue increasing by 11.7% for the quarter and 6.8% year-to-date. However, profitability metrics show a mixed picture. While net income attributable to AMRX has turned positive for the quarter ($2.4M vs -$0.2M loss) and improved significantly year-to-date ($37.0M vs -$85.8M loss), the company experienced a net loss before income taxes for the quarter due to a substantial $31.4 million loss on refinancing. Operating income for the quarter decreased, but showed a significant increase year-to-date. Key risks include rising debt levels and increased operating expenses, which offset some of the revenue gains.

Key Financial Figures

• $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market

Filing Documents

• amrx-20250930.htm (10-Q) — 1999KB
• amrx-2025093010xqexx311.htm (EX-31.1) — 10KB
• amrx-2025093010xqexx312.htm (EX-31.2) — 10KB
• amrx-2025093010xqexx313.htm (EX-31.3) — 10KB
• amrx-2025093010xqexx321.htm (EX-32.1) — 5KB
• amrx-2025093010xqexx322.htm (EX-32.2) — 5KB
• amrx-2025093010xqexx323.htm (EX-32.3) — 5KB
• 0001723128-25-000062.txt ( ) — 10953KB
• amrx-20250930.xsd (EX-101.SCH) — 81KB
• amrx-20250930_cal.xml (EX-101.CAL) — 96KB
• amrx-20250930_def.xml (EX-101.DEF) — 365KB
• amrx-20250930_lab.xml (EX-101.LAB) — 807KB
• amrx-20250930_pre.xml (EX-101.PRE) — 587KB
• amrx-20250930_htm.xml (XML) — 2033KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Consolidated Statements of Operations 4 Consolidated Statements of Comprehensive Loss 5 Consolidated Balance Sheets 6 Consolidated Statements of Cash Flows 7 Consolidated Statements of Changes in Stockholders' (Deficiency) Equity 9

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.

Controls and Procedures

Controls and Procedures 46

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 47 Item 1A.

Risk Factors

Risk Factors 47 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3. Defaults Upon Senior Securities 47 Item 4. Mine Safety Disclosures 47 Item 5. Other Information 47 Item 6. Exhibits 49

Signatures

Signatures 50 1 Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q and other publicly available documents of Amneal Pharmaceuticals, Inc. contain "forward-looking statements" within the meaning of the safe harbor provisions of the United States ("U.S.") Private Securities Litigation Reform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries ("the Company", "we", "us", or "our") also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "targets," "estimates," and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatory approvals; market position and expenditures. Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Summary of Material Risks Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differ materially from th

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) Amneal Pharmaceuticals, Inc. Consolidated Statements of Operations (unaudited; in thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net revenue $ 784,513 $ 702,468 $ 2,204,441 $ 2,063,439 Cost of goods sold 510,539 432,910 1,388,323 1,305,874 Gross profit 273,974 269,558 816,118 757,565 Selling, general and administrative 137,815 118,692 380,369 347,749 Research and development 63,352 61,097 151,356 136,449 Intellectual property legal development expenses 2,437 1,967 6,221 3,993 Restructuring and other charges 143 172 1,738 1,862 (Credit) charges related to legal matters, net — ( 149 ) ( 390 ) 94,909 Other operating income ( 117 ) ( 1,030 ) ( 5,239 ) ( 930 ) Operating income 70,344 88,809 282,063 173,533 Other (expense) income: Interest expense, net ( 62,814 ) ( 65,511 ) ( 184,854 ) ( 196,933 ) Foreign exchange (loss) gain, net ( 3,431 ) 2,274 9,072 815 Decrease (increase) in tax receivable agreement liability 20,808 ( 11,327 ) 5,701 ( 26,719 ) Loss on refinancing ( 31,365 ) — ( 31,365 ) — Other income, net 1,235 1,178 3,357 9,610 Total other expense, net ( 75,567 ) ( 73,386 ) ( 198,089 ) ( 213,227 ) Income (loss) before income taxes ( 5,223 ) 15,423 83,974 ( 39,694 ) (Benefit from) provision for income taxes ( 23,355 ) 3,666 5,614 13,440 Net income (loss) 18,132 11,757 78,360 ( 53,134 ) Less: Net income attributable to non-controlling interests ( 15,763 ) ( 11,913 ) ( 41,379 ) ( 32,671 ) Net income (loss) attributable to Amneal Pharmaceuticals, Inc. $ 2,369 $ ( 156 ) $ 36,981 $ ( 85,805 ) Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: Basic $ 0.01 $ ( — ) $ 0.12 $ ( 0.28 ) Diluted $ 0.01 $ ( — ) $ 0.11 $ ( 0.28 ) Weighted-average common shares outstanding: Basic 314,168 309,647 312,998 308,685 Diluted 324,754 309,647 323,704 308,685 The accompanying notes

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (unaudited) 1. Summary of Significant Accounting Policies Basis of Presentation The interim unaudited consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission and U.S. generally accepted accounting principles ("U.S. GAAP") for interim reporting. These financial statements include all adjustments that in the opinion of management are necessary for a fair presentation of the financial position, results of operations, and cash flows of Amneal Pharmaceuticals, Inc. (the "Company") for the periods presented. However, these financial statements do not include all information and accompanying notes required for annual financial statements prepared in accordance with U.S. GAAP. The interim unaudited consolidated financial statements should be read in conjunction with the audited annual financial statements included in the Company's 2024 Annual Report on Form 10-K. Use of Estimates The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-liv

View Full Filing

View this 10-Q filing on SEC EDGAR